Lack of Clinical Disease Activity Response at 4 Weeks of Baricitinib Treatment as a Negative Predictor of Remission at Weeks 12 and 24 in Patients with Rheumatoid Arthritis: Results from Two Phase 3 Studies (RA-BEAM and RA-BEGIN)